After several years of litigation, the fate of two patents owned by Bayer Intellectual Property GmbH (Bayer) covering dosages and uses of rivaroxaban has culminated in revocation and a...
After several years of litigation, the fate of two patents owned by Bayer Intellectual Property GmbH (Bayer) covering dosages...